Chemotherapy Agents: Onconase
ONCONASE is an agent that is meant to target cancerous cells while sparing healthy cells from side effects. ONCONASE is taken into cancerous cells, where it kills the cell through various processes.
Onconase is designed to inhibit cancer cell growth and viral replication. It works by inducing the intracellular decay of RNA. This in turn inhibits the cellular growth of the tumor. It also seems to enhance the anti-cancer effects of conventional chemotherapy.
Onconase seems to be effective against most tumors (e.g. kidney, breast, lung, prostate), and is especially effective against carcinomas (i.e. solid tumor cancers.)
Go to Onconase Clinical Program for more information concerning Phase III trials involving this treatment.
Alfacell Corporation Announced In Vivo Study Results. The Alfacell Corporation has evaluated Onconase® in over 850 patients with a variety of solid tumors in Phase I to Phase III studies (3/29/07)
ONCONASE ® plus doxorubicin vs. doxorubicin for patients with Malignant Pleural or Peritoneal Mesothelioma who have had no more than one prior chemotherapy regimen (8/16/05)
Update on Phase III Program of ONCONASE(R) for The Treatment of Patients with Unresectable Malignant Mesothelioma (4/18/02)
Phase II Trial of a Single Weekly Intravenous Dose of Ranpirnase (Onconase) in Patients With Unresectable Malignant Mesothelioma (12/31/01
Beating the Odds: Experimental Drug Offer Hope to Patients As a Promising Treatment For Mesothelial Cancer (5/11/01)
Phase III Results: ONCONASE Vs. Doxorubicin Presented At ASCO Meeting: ONCONASE Shows Survival Benefit in Patients with Malignant Mesothelioma (5/25/00 )
Dr. Mikulski Explains Why mesothelioma Patients Should Participate in Phase III Clinical Trial (Onconase/Doxorubicin vs. Doxorubicin). (8/6/99)